To include your compound in the COVID-19 Resource Center, submit it here.

ThromboGenics stops diabetic retinopathy trial due to slow enrollment

ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow

Read the full 239 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE